IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+13.89%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1B
AUM Growth
+$1B
(-1.4%)
Cap. Flow
-$24.3M
Cap. Flow
% of AUM
-2.42%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
99
New
22
Increased
29
Reduced
11
Closed
29
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29.8M |
| 2 |
Becton Dickinson
BDX
|
$17.5M |
| 3 |
Insmed
INSM
|
$16.8M |
| 4 |
Elevance Health
ELV
|
$16.3M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$14M |
Top Sells
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
$28.2M |
| 2 |
AbbVie
ABBV
|
$24.6M |
| 3 |
Intuitive Surgical
ISRG
|
$17.8M |
| 4 |
Charles River Laboratories
CRL
|
$17.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$16.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$7.43B
| $12.6M | 1.2% |
325,000
-95,000
| -23% | -$3.69M |
|
27
Amgen
AMGN
$153B
| $12.5M | 1.19% |
+40,000
| New | +$12.5M |
|
28
Ionis Pharmaceuticals
IONS
$9.64B
| $11.9M | 1.13% |
+250,000
| New | +$11.9M |
|
29
McKesson
MCK
$85.9B
| $11.7M | 1.11% |
+20,000
| New | +$11.7M |
|
30
Regenxbio
RGNX
$498M
| $11.1M | 1.06% |
950,000
+190,000
| +25% | +$2.22M |
|
|
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.93M | 0.94% |
145,000
+20,000
| +16% | +$1.37M |
|
32
Sanofi
SNY
$122B
| $9.7M | 0.92% |
+200,000
| New | +$9.7M |
|
33
MoonLake Immunotherapeutics
MLTX
$3.78B
| $9.67M | 0.92% |
220,000
| – | – |
|
34
Neurocrine Biosciences
NBIX
$13.5B
| $9.64M | 0.92% |
70,000
-80,000
| -53% | -$11M |
|
35
Teleflex
TFX
$5.57B
| $9.46M | 0.9% |
+45,000
| New | +$9.46M |
|
36
Eli Lilly
LLY
$661B
| $9.05M | 0.86% |
10,000
-2,000
| -17% | -$1.81M |
|
37
Globus Medical
GMED
$7.94B
| $8.56M | 0.81% |
+125,000
| New | +$8.56M |
|
38
Bruker
BRKR
$4.45B
| $8.3M | 0.79% |
130,000
-90,000
| -41% | -$5.74M |
|
39
CRISPR Therapeutics
CRSP
$4.82B
| $8.1M | 0.77% |
150,000
-70,000
| -32% | -$3.78M |
|
40
Oscar Health
OSCR
$4.57B
| $7.91M | 0.75% |
500,000
| – | – |
|
41
Repligen
RGEN
$6.54B
| $7.56M | 0.72% |
60,000
+10,000
| +20% | +$1.26M |
|
42
Denali Therapeutics
DNLI
$2.24B
| $7.55M | 0.72% |
+325,000
| New | +$7.55M |
|
43
Tenaya Therapeutics
TNYA
$192M
| $7.21M | 0.68% |
2,325,000
+75,000
| +3% | +$233K |
|
44
Sana Biotechnology
SANA
$759M
| $6.55M | 0.62% |
1,200,000
+220,000
| +22% | +$1.2M |
|
45
Elanco Animal Health
ELAN
$8.62B
| $6.49M | 0.62% |
450,000
-100,000
| -18% | -$1.44M |
|
|
MREO
46
Mereo BioPharma
MREO
$275M
| $6.39M | 0.61% |
1,775,000
+825,000
| +87% | +$2.97M |
|
47
Merus
MRUS
$5.04B
| $5.92M | 0.56% |
100,000
-65,000
| -39% | -$3.85M |
|
48
Insulet
PODD
$24.2B
| $5.05M | 0.48% |
+25,000
| New | +$5.05M |
|
49
QuidelOrtho
QDEL
$1.87B
| $4.98M | 0.47% |
+150,000
| New | +$4.98M |
|
50
Relay Therapeutics
RLAY
$709M
| $4.89M | 0.46% |
750,000
+25,000
| +3% | +$163K |
|